USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: NOVELMED THERAPEUTICS, INC.
City: CLEVELAND
State: OH
Zip+4: 44106-0000
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: Yes
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,410,120.00 13
SBIR Phase II $8,147,600.00 7
STTR Phase I $208,148.00 1

Award List:

Anti-Properdin MoAb as a Novel Therapeutic for Arthritis

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $103,103.00
Abstract:
DESCRIPTION (provided by applicant): The complement system is an important host defense system, however, inappropriate and/or excessive activation of the complement system has been implicated as contributing to the pathogenesis of many disease states, including rheumatoid arthritis (RA).… More

Novel Anti-Inflammatories for Cardiopulmonary Bypass

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $206,911.00
Abstract:
The complement system is an important host defense system, however, inappropriate and/or excessive activation of the complement system has been implicated as contributing to the pathogenesis of many disease states, including post-cardiopulmonary bypass. There is evidence that the complement… More

Anti-Properdin MoAb as a novel therapeutics for arthritis

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $825,534.00
Abstract:
DESCRIPTION (provided by applicant): Current therapeutic approaches for treating rheumatoid arthritis (RA) are not adequate to prevent the devastating inflammation and joint destruction. Complement activation contributes significantly to the inflammatory process in arthritic joints. While complement… More

Novel Anti-Inflammatories for Cardiopulmonary Bypass

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,485,330.00
Abstract:
DESCRIPTION (provided by applicant): There is evidence that the complement alternative pathway (AP) contributes significantly to the generation of pro-inflammatory agents in post-CPB inflammation. Complement activation products such as C3a, C5a, and C5b-9 have been found in blood samples of… More

Small Molecule TNF-alpha Inhibitor for the Treatment of Arthritis

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $249,927.00
Abstract:
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with joint inflammation, destruction, deformities, and increased mortality rates that affect 1.3 million Americans. Current approaches for treating RA are inadequate in preventing the… More

Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $233,538.00
Abstract:
DESCRIPTION (provided by applicant): Approximately 400,000 people with end stage renal disease undergo hemodialysis in the United States each year. During the hemodialysis procedure, the patient's blood circulates through the dialyzer and back to the patie nt. As a result, the patient's blood… More

Anti-Inflammatory Cardiovascular Device

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $273,190.00
Abstract:
DESCRIPTION (provided by applicant): NovelMed is developing an extracorporeal device which can be used to prevent complications associated with cardiac procedures where the patients' blood is exposed to artificial surfaces and ischemic/dead tissues. It is well known that the surfaces of plastics… More

Complement Inhibitors for Macular Degeneration

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $212,118.00
Abstract:
DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) affects nearly 10 million people in the U.S (Research to Prevent Blindness Foundation). Recently approved anti-VEGF therapy is the only cure for wet AMD as of today. Recent studies have demonstrated the role of the… More

Device for Surgical Adhesion Prevention

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $266,001.00
Abstract:
DESCRIPTION (provided by applicant): Postoperative adhesion formation is the single greatest complication of surgery. Twenty seven million surgical procedures are performed annually in the U.S. where the patient is at risk for the complications from surgic al adhesions. After surgery, fibrous… More

Controlling Inflammation Due to Cardiac Devices

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $420,195.00
Abstract:
DESCRIPTION (provided by applicant): NovelMed's lead drug candidate prevents biomaterials induced cellular activation. Activated cells release inflammatory mediators that are responsible for pathological trauma that leads to cardiac, lung, liver, and brain injuries during surgical procedures that… More

Neutralizing Antibodies for Complement Inhibition

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $300,000.00
Abstract:
DESCRIPTION (provided by applicant): Ischemia-reperfusion (I/R) injury is a common clinical event, which has the potential to seriously affect, and sometimes result in death, of the patient. Interruption of the blood supply causes ischemia, which rapidly d amages metabolically active tissues.… More

Inhibition of Cardiac Device Induced Cellular Dysfunction in Pigs

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $516,118.00
Abstract:
DESCRIPTION (provided by applicant): Artificial surfaces of cardiac devices induce cellular activation and platelet dysfunction in patients undergoing bypass procedure. While other pathways may be activated during this process, alternative pathway (AP) act ivation appears to be one of the important… More

Disease Modifying Biologics for Rheumatoid Arthritis

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal
Award Amount: $791,681.00
Abstract:
DESCRIPTION (provided by applicant): Nearly 70 million people in the US suffer from arthritis related conditions[1, 2]. Of these, rheumatoid arthritis (RA) cases constitute approximately 3 million. RA is a chronic systemic inflammatory disease that pri marily results in erosive destruction of… More

Disease Modifying Biologics for Rheumatoid Arthritis

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Rekha Bansal – 440-477-9874
Award Amount: $1,916,919.00
Abstract:
DESCRIPTION (provided by applicant): Nearly 70 million people in the US suffer from arthritis related conditions[1, 2]. Of these, rheumatoid arthritis (RA) cases constitute approximately 3 million. RA is a chronic systemic inflammatory disease that primarily results in erosive destruction of… More

Controlling Inflammation Due to Cardiac Devices

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Rekha Bansal – 440-477-9874
Award Amount: $1,352,967.00
Abstract:
DESCRIPTION (provided by applicant): NovelMed's lead drug candidate prevents biomaterials induced cellular activation. Activated cells release inflammatory mediators that are responsible for pathological trauma that leads to cardiac, lung, liver, and braininjuries during surgical procedures… More

Inhibition of Cardiac Device Induced Cellular Dysfunction in Pigs

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Rekha Bansal – 440-477-9874
Award Amount: $1,194,729.00
Abstract:
DESCRIPTION (provided by applicant): Artificial surfaces of cardiac devices induce cellular activation and platelet dysfunction in patients undergoing bypass procedure. While other pathways may be activated during this process, alternative pathway (AP) activation appears to be one of the important… More

Complement Inhibitors for Macular Degeneration

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Rekha Bansal – 440-477-9874
Award Amount: $1,064,251.00
Abstract:
DESCRIPTION (provided by applicant): According to the World Health Organization (WHO) global eye disease survey, 14 million people are blind or severely visually impaired due to age-related macular degeneration AMD. This disease affects the central visionof adults over the age 65. Degenerative… More

Complement Inhibitors as DMOADs

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal – 440-477-9874
Award Amount: $294,766.00
Abstract:
DESCRIPTION (provided by applicant): Complement system play a role in preventing inflammation and joint immobility. Osteoarthritis (OA), an inflammatory disease of the joints, is quite prevalent among the elderly and causes disability in nearly 10% of thepopulation over 55 years. Current… More

Set2Read-AK (Alphabet Knowledge)

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rekha Bansal – 440-477-9874
Award Amount: $542,572.00
Abstract:
DESCRIPTION (provided by applicant): Paroxysmal Nocturnal Hemoglobinuria (PNH) is an orphan disease characterized by severe anemia, kidney and liver failure, and ultimately death, if left untreated. In 2007, FDA approved the first complement inhibitor, Eculizumab (Soliris(R)), for the treatment of… More

Complement Inhibitors as DMOADs

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Rekha Bansal – 440-477-9874
Award Amount: $307,870.00
Abstract:
DESCRIPTION (provided by applicant): Complement system play a role in preventing inflammation and joint immobility. Osteoarthritis (OA), an inflammatory disease of the joints, is quite prevalent among the elderly and causes disability in nearly 10% of thepopulation over 55 years. Current… More